Shots:
- Bluejay Therapeutics has enrolled its first patient in the P-III (AZURE-2) trial assessing brelovitug (300mg, SC, QW) vs Hepcludex (bulevirtide) for the treatment of chronic hepatitis D
- Trial will assess the proportion of participants achieving a composite response at Wk. 48, defined as undetectable hepatitis D virus RNA along with normalization of alanine aminotransferase (ALT), as the 1EP
- Brelovitug is also being evaluated in P-IIb/III (AZURE-1) trial against 24wks. of delayed treatment for chronic hepatitis D infection, with enrolment ongoing across the US & other regions
Ref: Bluejay Therapeutics | Image: Bluejay Therapeutics | Press Release
Related News:- Ionis Reveals Topline P-III (CORE & CORE2) Trial Data of Olezarsen for Severe Hypertriglyceridemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
